Inhibitors targeting the catalytic domain of mTOR have also been developed [118], and pre-clinical studies of rapamycin combined with rapalogs targeted at mTOR showed inhibition of clonogenic AML cell proliferation without inhibition of normal CD34+ cells [97]. This evidence concerns the gene CD34 and acute myeloid leukemia.